Managing Complex Cases in Glaucoma
Elevated intraocular pressure (IOP), and perhaps its variability, is the only modifiable risk factor for glaucoma progression that has also been rigorously proven as a treatment for glaucoma. Given this role of IOP in glaucoma, current therapy and management practices focus on reducing IOP and maintaining it at acceptable target levels to prevent damage to the optic nerve and visual field. While the number of treatment options to control IOP has increased, a cure is not yet available. Newer technologies and agents continue to be explored; however, until a cure is discovered, physicians rely on medical and interventional therapy: topical IOP lowering agents including the mainstay, prostaglandin analogs, along with carbonic anhydrase inhibitor (CAI) and beta-blocker topical therapies, and laser (ALT or SLT) or surgical interventions may be employed. » Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.